Volume 87, Issue 3, Pages (March 2015)

Slides:



Advertisements
Similar presentations
LDL cholesterol in CKD—to treat or not to treat?
Advertisements

Volume 81, Issue 5, Pages (March 2012)
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:
KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient  Christoph Wanner,
Frederik Persson, Peter Rossing  Kidney International Supplements 
Anemia management in chronic kidney disease
Mitchell H. Rosner, W. Kline Bolton  Kidney International 
Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis  Patricia M.
Volume 83, Issue 3, Pages (March 2013)
Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure  Steven Fishbane, Nobuyuki Miyawaki  Kidney International 
ESA and iron therapy in chronic kidney disease: a balance between patient safety and hemoglobin target  Szu-Chun Hung, Der-Cherng Tarng  Kidney International 
Gudrun Hatlen, Solfrid Romundstad, Stein I. Hallan 
Prehypertension and chronic kidney disease: the ox or the plow?
Status of chronic kidney disease prevention programs: International Federation of Kidney Foundation Members 2005/2007  Joanna M. Smith, Susan A. Mott,
Reassessment of the care of the patient with chronic kidney disease
C-reactive protein and dialysis access
John P. Middleton, Patrick H. Pun  Kidney International 
Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study  Vasilios Papademetriou, MD, DSc, Eric.
Need for better diabetes treatment for improved renal outcome
Volume 72, Issue 10, Pages (November 2007)
Yasuhiro Hamada, Masafumi Fukagawa  Kidney International 
Jeffrey C. Fink, Glenn M. Chertow  Kidney International 
Volume 70, Pages S21-S25 (December 2006)
Steroid-free maintenance immunosuppression in kidney transplantation: is it time to consider it as a standard therapy?  Fu L. Luan, Diane E. Steffick,
Volume 75, Issue 10, Pages (May 2009)
Steven G. Coca, Swathi Singanamala, Chirag R. Parikh 
Volume 72, Issue 6, Pages (September 2007)
Comorbidity and confounding in end-stage renal disease
D. Batlle, P. Ramadugu, M.J. Soler  Kidney International 
Acute myocardial infarction in patients with chronic kidney disease: how are the most vulnerable patients doing?  Gautam R. Shroff, Charles A. Herzog 
The importance of increased dialysis and anemia management for infant survival in pregnant women on hemodialysis  Sai Subhodhini Reddy, Jean L. Holley 
Volume 74, Issue 3, Pages (August 2008)
Volume 70, Issue 11, Pages (December 2006)
The epidemiology of chronic kidney disease
Use of vitamin D in chronic kidney disease patients
Volume 75, Issue 1, Pages (January 2009)
Pieter Evenepoel, Björn K. Meijers  Kidney International 
LDL cholesterol in CKD—to treat or not to treat?
Volume 74, Issue 8, Pages (October 2008)
The calcium–phosphorus in guidelines for CKD-MBD
Volume 81, Issue 5, Pages (March 2012)
Volume 73, Issue 12, Pages (June 2008)
Volume 76, Issue 6, Pages (September 2009)
Volume 81, Issue 6, Pages (March 2012)
Extracorporeal therapy in sepsis: are we there yet?
Tilman B. Drüeke, Ziad A. Massy  Kidney International 
Alternate-day dialysis may be needed for hemodialysis patients
Methods for guideline development
Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes  J.-L. Lin, D.-T. Lin-Tan, C.-C. Yu, Y.-J. Li, Y.-Y.
Volume 87, Issue 1, Pages (January 2015)
Nephrology Crossword: Glomerulonephritis
A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease  S. Susan Hedayati, Venkata Yalamanchili,
Will there be an epidemic of HIV-related chronic kidney disease in sub-Saharan Africa? Too soon to tell  Kara K. Wools-Kaloustian, Samir K. Gupta  Kidney.
Vitamin D in chronic kidney disease: is the jury in?
Volume 64, Issue 2, Pages (August 2003)
Cardio-Kidney-Damage: a unifying concept
Volume 72, Issue 2, Pages (July 2007)
Volume 80, Issue 10, Pages (November 2011)
Cardiovascular risk in chronic kidney disease
Volume 75, Issue 1, Pages (January 2009)
The hypothesis that abnormal BH4 metabolism impairs kidney function
Volume 86, Issue 2, Pages (August 2014)
Volume 75, Issue 7, Pages (April 2009)
Volume 88, Issue 5, Pages (November 2015)
Antioxidant therapy in hemodialysis patients: a systematic review
In chronic kidney disease staging the use of the chronicity criterion affects prognosis and the rate of progression  B.O. Eriksen, O.C. Ingebretsen  Kidney.
Rajni Singhal, Janet E. Hux, Shabbir M H Alibhai, Matthew J. Oliver 
Stephen Pastan, J. Michael Soucie, William M. McClellan 
Sugar-sweetened beverages and chronic disease
Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies  Lei-Shi Li, Zhi-Hong Liu  Kidney International 
Presentation transcript:

Volume 87, Issue 3, Pages 649-659 (March 2015) Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes  Vasilios Papademetriou, Laura Lovato, Michael Doumas, Eric Nylen, Amy Mottl, Robert M. Cohen, William B. Applegate, Zubin Puntakee, Jean Francois Yale, William C. Cushman  Kidney International  Volume 87, Issue 3, Pages 649-659 (March 2015) DOI: 10.1038/ki.2014.296 Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 1 Glycated hemoglobin levels with intensive and standard therapy in patients with or without chronic kidney disease (CKD). FU, follow-up; Int, intensive; Std, standard. Kidney International 2015 87, 649-659DOI: (10.1038/ki.2014.296) Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 2 Rates for the primary and secondary outcomes in patients with and without chronic kidney disease (CKD). Kidney International 2015 87, 649-659DOI: (10.1038/ki.2014.296) Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 3 Rates of primary and secondary outcomes by chronic kidney disease status. Rates for the primary and secondary outcomes in patients without CKD compared to patients with mild CKD I and II (a), CKD III (b) and albuminuria (c). Kidney International 2015 87, 649-659DOI: (10.1038/ki.2014.296) Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 3 Rates of primary and secondary outcomes by chronic kidney disease status. Rates for the primary and secondary outcomes in patients without CKD compared to patients with mild CKD I and II (a), CKD III (b) and albuminuria (c). Kidney International 2015 87, 649-659DOI: (10.1038/ki.2014.296) Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 4 Rates of primary and secondary outcomes by randomized treatment group (intensive versus standard). Rates for the primary and secondary outcomes with intensive versus standard glycemic therapy in patients with chronic kidney disease (CKD) (a) and non CKD (b). Kidney International 2015 87, 649-659DOI: (10.1038/ki.2014.296) Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 5 Cardiovascular and all-cause mortality stratified by intensive or standard treatment group and by chronic kidney disease (CKD) status. Cardiovascular and all-cause mortality with intensive versus standard glycemic control in patients without CKD (a, c) and with CKD (b, d). Kidney International 2015 87, 649-659DOI: (10.1038/ki.2014.296) Copyright © 2015 International Society of Nephrology Terms and Conditions